Emil D. Kakkis's most recent trade in Ultragenyx Pharmaceutical Inc. was a trade of 107,292 Common Stock done . Disclosure was reported to the exchange on Feb. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 107,292 | 715,165 (1%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 78,448 | 78,448 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 42.10 per share. | 28 Feb 2025 | 73,434 | 641,731 (1%) | 0% | 42.1 | 3,091,571 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 43,268 | 607,873 (1%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 42.48 per share. | 28 Feb 2025 | 25,000 | 2,158,985 (3%) | 0% | 42.5 | 1,062,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 42.23 per share. | 30 Dec 2024 | 11,727 | 2,183,985 (3%) | 0% | 42.2 | 495,231 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Dec 2024 | 20,000 | 2,203,985 (3%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 09 Dec 2024 | 8,273 | 2,195,712 (3%) | 0% | 50 | 413,650 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 55.85 per share. | 03 Sep 2024 | 20,000 | 2,223,985 (3%) | 0% | 55.9 | 1,117,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 50.17 per share. | 06 Aug 2024 | 20,000 | 2,243,985 (3%) | 0% | 50.2 | 1,003,400 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 70,094 | 70,094 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 38,428 | 578,198 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.69 per share. | 01 Mar 2024 | 17,417 | 560,781 (0%) | 0% | 53.7 | 935,119 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 3,132 | 563,913 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Emil Kakkis D. | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 07 Feb 2024 | 30,000 | 539,770 (0%) | 0% | 45 | 1,350,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Kakkis Emil D. | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 47.87 per share. | 29 Dec 2023 | 30,000 | 569,770 (0%) | 0% | 47.9 | 1,436,100 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 83,500 | 83,500 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 46,200 | 615,606 (1%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.65 per share. | 01 Mar 2023 | 16,140 | 599,176 (1%) | 0% | 45.7 | 736,791 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 8,716 | 569,406 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 45.57 per share. | 30 Dec 2022 | 19,582 | 541,108 (0%) | 0% | 45.6 | 892,352 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 92,360 | 92,360 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 52,041 | 634,226 (1%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 67.37 per share. | 01 Mar 2022 | 12,162 | 582,185 (1%) | 0% | 67.4 | 819,354 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.00 per share. | 14 Oct 2021 | 853 | 594,347 (1%) | 0% | 81 | 69,093 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.71 per share. | 06 May 2021 | 852 | 595,200 (1%) | 0% | 115.7 | 98,585 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 107.80 per share. | 03 May 2021 | 30,000 | 2,259,741 (3%) | 0% | 107.8 | 3,234,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 141.80 per share. | 01 Mar 2021 | 30,000 | 2,289,741 (3%) | 0% | 141.8 | 4,254,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 18,000 | 596,941 (1%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 142.47 per share. | 01 Mar 2021 | 16,342 | 596,052 (1%) | 0% | 142.5 | 2,328,245 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 15,453 | 612,394 (1%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 136.90 per share. | 04 Jan 2021 | 30,000 | 2,329,741 (4%) | 0% | 136.9 | 4,107,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.69 per share. | 14 Oct 2020 | 852 | 610,189 (1%) | 0% | 92.7 | 78,972 | Common Stock |
| Ultragenyx Pharmaceutical ... | Emil D. Kakkis | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 82.63 per share. | 01 Sep 2020 | 30,000 | 2,389,741 (4%) | 0% | 82.6 | 2,478,900 | Common Stock |